Repository logo
 
Publication

Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients

dc.contributor.authorLonghi, A
dc.contributor.authorBielack, SS
dc.contributor.authorGrimer, R
dc.contributor.authorWhelan, J
dc.contributor.authorWindhager, R
dc.contributor.authorLeithner, A
dc.contributor.authorGronchi, A
dc.contributor.authorBiau, D
dc.contributor.authorJutte, P
dc.contributor.authorKrieg, AH
dc.contributor.authorKlenke, FM
dc.contributor.authorGrignani, G
dc.contributor.authorDonati, DM
dc.contributor.authorCapanna, R
dc.contributor.authorCasanova, J
dc.contributor.authorGerrand, C
dc.contributor.authorBisogno, G
dc.contributor.authorHecker-Nolting, S
dc.contributor.authorDe Lisa, M
dc.contributor.authorD'Ambrosio, L
dc.contributor.authorWillegger, M
dc.contributor.authorScoccianti, G
dc.contributor.authorFerrari, S
dc.date.accessioned2017-09-01T10:28:11Z
dc.date.available2017-09-01T10:28:11Z
dc.date.issued2017-03
dc.description.abstractPURPOSE: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective study aimed to evaluate factors influencing ESOS prognosis. PATIENTS AND METHODS: Members of the European Musculoskeletal Oncology Society (EMSOS) submitted institutional data on patients with ESOS. RESULTS: Data from 274 patients treated from 1981 to 2014 were collected from 16 EMSOS centres; 266 patients were eligible. Fifty (18.7%) had metastases at diagnosis. Of 216 patients with localised disease, 211 (98%) underwent surgery (R0 = 70.6%, R1 = 27%). Five-year overall survival (OS) for all 266 patients was 47% (95% CI 40-54%). Five-year OS for metastatic patients was 27% (95% CI 13-41%). In the analysis restricted to the 211 localised patients who achieved complete remission after surgery 5-year OS was 51.4% (95% CI 44-59%) and 5-year disease-free survival (DFS) was 43% (95% CI 35-51%). One hundred twenty-one patients (57.3%) received adjuvant or neoadjuvant chemotherapy and 80 patients (37.9%) received radiotherapy. A favourable trend was seen for osteosarcoma-type chemotherapy versus soft tissue sarcoma-type (doxorubicin ± ifosfamide) regimens. For the 211 patients in complete remission after surgery, patient age, tumour size, margins and chemotherapy were positive prognostic factors for DFS and OS by univariate analysis. At multivariate analysis, patient age (≤40 years versus >40 years) (P = 0.05), tumour size (P = 0.0001) and receipt of chemotherapy (P = 0.006) were statistically significant prognostic factors for survival. CONCLUSION: Patient age and tumour size are factors influencing ESOS prognosis. Higher survival was observed in patients who received perioperative chemotherapy with a trend in favour of multiagent osteosarcoma-type regimen which included doxorubicin, ifosfamide and cisplatin.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEur J Cancer. 2017 Mar;74:9-16pt_PT
dc.identifier.doi10.1016/j.ejca.2016.12.016pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.4/2088
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectQuimiorradioterapiapt_PT
dc.subjectOsteosarcomapt_PT
dc.subjectNeoplasias dos Tecidos Molespt_PT
dc.subjectEuropapt_PT
dc.titleExtraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patientspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage16pt_PT
oaire.citation.startPage9-16pt_PT
oaire.citation.volume74pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Extraskeletal osteosarcoma.pdf
Size:
506.74 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections